These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23581963)

  • 1. Alemtuzumab induction in pediatric kidney transplantation.
    Nguyen C; Shapiro R
    Pediatr Transplant; 2013 Jun; 17(4):319-20. PubMed ID: 23581963
    [No Abstract]   [Full Text] [Related]  

  • 2. Alemtuzumab induction in pediatric kidney transplantation.
    Kaabak MM; Babenko NN; Samsonov DV; Sandrikov VA; Maschan AA; Zokoev AK
    Pediatr Transplant; 2013 Mar; 17(2):168-78. PubMed ID: 23442101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC
    Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induction therapy in kidney transplantation.
    Dhaun N; Kluth DC
    Lancet; 2015 Feb; 385(9970):770. PubMed ID: 25752171
    [No Abstract]   [Full Text] [Related]  

  • 5. Alemtuzumab induction therapy in kidney transplantation.
    Berghofen A; Singer T; Krüger B; Krämer BK; Benck U
    Lancet; 2015 Feb; 385(9970):770-1. PubMed ID: 25752170
    [No Abstract]   [Full Text] [Related]  

  • 6. Alemtuzumab induction therapy in kidney transplantation.
    Kuypers DR
    Lancet; 2014 Nov; 384(9955):1649-51. PubMed ID: 25078307
    [No Abstract]   [Full Text] [Related]  

  • 7. Alemtuzumab induction therapy in kidney transplantation - Authors' reply.
    Haynes R; Baigent C; Landray MJ; Harden P; Friend P
    Lancet; 2015 Feb; 385(9970):771. PubMed ID: 25752173
    [No Abstract]   [Full Text] [Related]  

  • 8. Postoperative cardiac tamponade after kidney transplantation: a possible consequence of alemtuzumab-induced cytokine release syndrome.
    Adams PS; Shapiro R; Hilmi IA
    Transplantation; 2013 Feb; 95(3):e18-9. PubMed ID: 23380870
    [No Abstract]   [Full Text] [Related]  

  • 9. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.
    Heilman RL; Khamash HA; Smith ML; Chakkera HA; Moss AA; Reddy KS
    Clin Transplant; 2013; 27(5):772-80. PubMed ID: 23924146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab with corticosteroid minimization for pediatric deceased donor renal transplantation: a seven-yr experience.
    Supe-Markovina K; Melquist JJ; Connolly D; DiCarlo HN; Waltzer WC; Fine RN; Darras FS
    Pediatr Transplant; 2014 Jun; 18(4):363-8. PubMed ID: 24712738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The search for the optimal antibody induction strategy in kidney transplantation: still "hazy" after all these years.
    Stratta RJ
    Clin Transplant; 2015 Jul; 29(7):569-72. PubMed ID: 25880305
    [No Abstract]   [Full Text] [Related]  

  • 12. Systematic reviews of alemtuzumab in renal transplantation.
    O'Callaghan JM; Morgan RD; Knight SR; Morris PJ
    Transpl Immunol; 2013 Mar; 28(2-3):71. PubMed ID: 23352935
    [No Abstract]   [Full Text] [Related]  

  • 13. Transplantation: Alemtuzumab induction reduces acute rejection risk.
    Sidaway P
    Nat Rev Nephrol; 2014 Oct; 10(10):542. PubMed ID: 25112441
    [No Abstract]   [Full Text] [Related]  

  • 14. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.
    Morgan RD; O'Callaghan JM; Knight SR; Morris PJ
    Transplantation; 2012 Jun; 93(12):1179-88. PubMed ID: 22660659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE; Enderby CY; Gonwa TA; Wadei HM
    Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of alemtuzumab in organ transplantation: current clinical status.
    Ciancio G; Burke GW; Warque ME; Miller J
    BioDrugs; 2006; 20(2):85-92. PubMed ID: 16626166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HLA-incompatibility and kidney transplant: a question of desensitization].
    Grosjean F
    G Ital Nefrol; 2011; 28(6):581. PubMed ID: 22167608
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.
    Plata-Munoz JJ; Vaidya A; Fuggle SV; Friend PJ
    Transpl Int; 2009 Oct; 22(10):1024-7. PubMed ID: 19624499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.